These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 28593681)

  • 1. Initial anticoagulation in patients with pulmonary embolism: thrombolysis, unfractionated heparin, LMWH, fondaparinux, or DOACs?
    Leentjens J; Peters M; Esselink AC; Smulders Y; Kramers C
    Br J Clin Pharmacol; 2017 Nov; 83(11):2356-2366. PubMed ID: 28593681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin.
    Prescrire Int; 2013 Apr; 22(137):99-101, 103-4. PubMed ID: 23662321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute pulmonary embolism. Part 2: treatment.
    van Es J; Douma RA; Gerdes VE; Kamphuisen PW; Büller HR
    Nat Rev Cardiol; 2010 Nov; 7(11):613-22. PubMed ID: 20842179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antithrombotic Treatment of Pulmonary Embolism].
    Ebner M; Lankeit M
    Dtsch Med Wochenschr; 2020 Jul; 145(14):970-977. PubMed ID: 32668468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on pharmacologic therapy for pulmonary embolism.
    Harikrishnan P; Palaniswamy C; Aronow WS
    J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):159-69. PubMed ID: 24177334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
    Akl EA; Kahale L; Neumann I; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2014 Jun; (6):CD006649. PubMed ID: 24945634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current perspectives on the treatment of venous thromboembolism: need for effective, safe and convenient new antithrombotic drugs.
    O'Shaughnessy DF
    Int J Clin Pract; 2004 Mar; 58(3):277-84. PubMed ID: 15117096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
    Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2011 Jun; (6):CD006649. PubMed ID: 21678360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
    Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2011 Feb; (2):CD006649. PubMed ID: 21328285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Kearon C; Kahn SR; Agnelli G; Goldhaber S; Raskob GE; Comerota AJ
    Chest; 2008 Jun; 133(6 Suppl):454S-545S. PubMed ID: 18574272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New-generation anticoagulants: the low molecular weight heparins.
    Hovanessian HC
    Ann Emerg Med; 1999 Dec; 34(6):768-79. PubMed ID: 10577408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
    Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic approaches to acute pulmonary embolism].
    Reissig A; Kroegel C
    Internist (Berl); 2004 May; 45(5):540-8. PubMed ID: 15054574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombolytic therapy for submassive pulmonary embolism.
    Lankeit M; Konstantinides S
    Best Pract Res Clin Haematol; 2012 Sep; 25(3):379-89. PubMed ID: 22959553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The low molecular weight heparin, tinzaparin, in thrombosis and beyond.
    Mousa SA
    Cardiovasc Drug Rev; 2002; 20(3):199-216. PubMed ID: 12397367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suboptimal management of unfractionated heparin compared with low-molecular-weight heparin in the management of pulmonary embolism.
    Khor YH; Smith R; McDonald CF
    Intern Med J; 2014 Apr; 44(4):339-44. PubMed ID: 24877250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.
    Büller HR; Davidson BL; Decousus H; Gallus A; Gent M; Piovella F; Prins MH; Raskob G; van den Berg-Segers AE; Cariou R; Leeuwenkamp O; Lensing AW;
    N Engl J Med; 2003 Oct; 349(18):1695-702. PubMed ID: 14585937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking inhibition of prothrombinase by tissue factor pathway inhibitor alpha: a procoagulant property of heparins.
    Wood JP; Baumann Kreuziger LM; Desai UR; Mast AE
    Br J Haematol; 2016 Oct; 175(1):123-32. PubMed ID: 27301751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
    Hillis C; Crowther MA
    Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inverse relationship of bleeding risk with clot burden during pulmonary embolism treatment with LMW heparin.
    Wang C; Zhai Z; Yang Y; Cheng Z; Ying K; Liang L; Dai H; Huang K; Lu W; Zhang Z; Cheng X; Shen YH; Davidson BL;
    Clin Respir J; 2016 Sep; 10(5):596-605. PubMed ID: 25619125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.